Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Kerala Ayurveda's board met on Feb 12, 2026 and approved multiple items. Standalone Q3 FY26 revenue rose to Rs. 22.07 crore (from Rs. 19.35 crore YoY), but loss after tax widened sharply to Rs. 3.47 crore (vs Rs. 0.08 crore). For 9M FY26, standalone loss stood at Rs. 6.81 crore against Rs. 5.41 crore revenue. The board approved issuing 6,30,000 equity shares at Rs. 327.99 each to promoter group entity Katra Holding Pvt Ltd to convert an outstanding unsecured loan of Rs. 20.66 crore. Additionally, it approved acquiring the remaining 26% stake in subsidiary Ayurvedagram Heritage Wellness Centre for Rs. 10 crore, paid via share swap (304,887 shares at Rs. 327.99), making it a wholly owned subsidiary. The NRC also granted 12,868 stock options at Rs. 10 per option under the ESOP 2023 scheme. An EGM is scheduled for March 14, 2026 to seek shareholder approval for these preferential issues.
This is a mixed development for shareholders: losses have deepened significantly despite revenue growth, suggesting cost pressures. The preferential allotments are dilutive (shares issued at Rs. 327.99) but represent debt-to-equity conversion and strategic subsidiary consolidation rather than cash outflow. Short-term stock may see pressure from dilution and continued losses; the subsidiary full ownership could unlock operational synergies over time.